| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.34 | 4e-14 |
| mRNA | OSI-930 | GDSC1000 | pan-cancer | AAC | 0.26 | 7e-14 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.25 | 3e-13 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | 0.26 | 4e-13 |
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | 0.24 | 1e-12 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | 0.24 | 2e-12 |
| mRNA | selumetinib:tretinoin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.24 | 3e-12 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | 0.24 | 1e-11 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.25 | 2e-11 |
| mRNA | KW-2449 | CTRPv2 | pan-cancer | AAC | 0.2 | 2e-11 |